mavacamten Camzyos
Selected indexed studies
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. (Lancet, 2020) [PMID:32871100]
- Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. (Eur Heart J, 2023) [PMID:37804245]
- Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. (Eur Heart J, 2024) [PMID:39217450]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. (2020) pubmed
- Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. (2023) pubmed
- Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. (2024) pubmed
- Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. (2025) pubmed
- Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. (2020) pubmed
- Mavacamten: First Approval. (2022) pubmed
- Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial. (2023) pubmed
- PMID:37797127 (2023) pubmed
- PMID:37643270 (2023) pubmed
- Mavacamten (Camzyos) for obstructive hypertrophic cardiomyopathy. (2022) pubmed